Cargando…
Vaccine or monoclonal therapy: which is the winning weapon against COVID-19?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260546/ https://www.ncbi.nlm.nih.gov/pubmed/34242802 http://dx.doi.org/10.1016/j.jgar.2021.05.021 |
| _version_ | 1783718829847740416 |
|---|---|
| author | Lo Muzio, Lorenzo Bizzoca, Maria Eleonora |
| author_facet | Lo Muzio, Lorenzo Bizzoca, Maria Eleonora |
| author_sort | Lo Muzio, Lorenzo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8260546 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82605462021-07-07 Vaccine or monoclonal therapy: which is the winning weapon against COVID-19? Lo Muzio, Lorenzo Bizzoca, Maria Eleonora J Glob Antimicrob Resist Short Communication The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. 2021-09 2021-07-07 /pmc/articles/PMC8260546/ /pubmed/34242802 http://dx.doi.org/10.1016/j.jgar.2021.05.021 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Short Communication Lo Muzio, Lorenzo Bizzoca, Maria Eleonora Vaccine or monoclonal therapy: which is the winning weapon against COVID-19? |
| title | Vaccine or monoclonal therapy: which is the winning weapon against COVID-19? |
| title_full | Vaccine or monoclonal therapy: which is the winning weapon against COVID-19? |
| title_fullStr | Vaccine or monoclonal therapy: which is the winning weapon against COVID-19? |
| title_full_unstemmed | Vaccine or monoclonal therapy: which is the winning weapon against COVID-19? |
| title_short | Vaccine or monoclonal therapy: which is the winning weapon against COVID-19? |
| title_sort | vaccine or monoclonal therapy: which is the winning weapon against covid-19? |
| topic | Short Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260546/ https://www.ncbi.nlm.nih.gov/pubmed/34242802 http://dx.doi.org/10.1016/j.jgar.2021.05.021 |
| work_keys_str_mv | AT lomuziolorenzo vaccineormonoclonaltherapywhichisthewinningweaponagainstcovid19 AT bizzocamariaeleonora vaccineormonoclonaltherapywhichisthewinningweaponagainstcovid19 |